← Back to Search

Vision Screening Tests for Childhood Eye Conditions

Phase 3
Waitlist Available
Research Sponsored by National Eye Institute (NEI)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Ages between 3 years 0 months and 4 years 11 months
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Study Summary

This trial is testing different vision screening tests to see which one can accurately predict which young children would benefit from a more comprehensive vision examination.

Who is the study for?
The VIP Study is for children enrolled in Head Start between the ages of 3 and almost 5. It's designed to find kids who might have lazy eye, need glasses, or have crossed eyes and would benefit from a full eye exam.Check my eligibility
What is being tested?
This study tests vision-screening methods to identify preschoolers at risk for amblyopia (lazy eye), strabismus (crossed eyes), and significant refractive errors that require corrective lenses.See study design

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 3 and 4 years old.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Find a Location

Who is running the clinical trial?

National Eye Institute (NEI)Lead Sponsor
546 Previous Clinical Trials
1,401,928 Total Patients Enrolled
3 Trials studying Refractive Errors
694 Patients Enrolled for Refractive Errors

Media Library

Treatment Clinical Trial Eligibility Overview. Trial Name: NCT00038753 — Phase 3
Refractive Errors Research Study Groups:
Refractive Errors Clinical Trial 2023: Treatment Highlights & Side Effects. Trial Name: NCT00038753 — Phase 3
Treatment 2023 Treatment Timeline for Medical Study. Trial Name: NCT00038753 — Phase 3
Refractive Errors Patient Testimony for trial: Trial Name: NCT00038753 — Phase 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Where are the different test sites for this study?

"Right now, there are 5 different sites where patients can be enrolled in this trial. They are situated in Boston, Philadelphia, Tahlequah and 2 other additional places. If it is possible for you, try to choose the location that is closest to you to limit travel time commitments."

Answered by AI

Is this drug legally allowed to be prescribed by medical doctors in the United States?

"This therapy received a safety score of 3 by our Power team. This is given because it is a Phase 3 trial, signifying that there are positive efficacy data as well as numerous rounds of safety testing data."

Answered by AI

Are young people welcome in this clinical trial?

"Children aged 36 months to 59 months can enroll in this trial, while there are other ongoing clinical trials for both younger and older patients."

Answered by AI

Who else is applying?

What portion of applicants met pre-screening criteria?
Did not meet criteria
Met criteria
How many prior treatments have patients received?
2
What site did they apply to?
Oklahoma Northeastern State University College of Optometry

Why did patients apply to this trial?

I've been to different eye doctors in my country but they don't seem to correctly diagnose my condition.
PatientReceived no prior treatments
Recent research and studies
clinicaltrials.govStudy
Vision In Preschoolers Study (VIP Study)
2024. "Vision In Preschoolers Study (VIP Study)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00038753.
All > Vision
~233 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top